Encompassing early BC, the NCCN Guidelines® recommend gBRCAm testing for all individuals who receive BC diagnoses at an early age (≤50 years) and for those diagnosed with TNBC, irrespective of their age, to aid in adjuvant treatment decisions with olaparib for high-risk, HER2-negative BC [25]. This evidence concerns the gene ERBB2 and breast cancer.